CordenPharma Switzerland


Managing Director:

Juerg Burger



CordenPharma Switzerland LLC

Eichenweg 1
4410 Liestal
Switzerland

Phone:+41 61 906 59 59
Fax:+41 61 906 59 58

Get Driving Directions:

Get Directions

US Customer Service 2075 North 55th Street
Boulder, CO 80301
US Toll Free: +1 800 868 8208
US Toll: +1 303 938 6488
Fax: +1 303 938 6590
Email: contactUS@cordenpharma.com


>>> New Brochure <<< Click here to read CordenPharma Switzerlands's New Brochure
 

Core Capabilities

Feasability Studies & Process Development

  • Experts for route scouting & process development for exclusive compounds & NCE APIs
    including key intermediates and chiral building blocks
  • Experts in developing and manufacturing APIs and other chemically synthesized materials (small and commercial scale)
  • Special expertise in lipids, peptides, carbohydrates, amino acid derivatives and other building blocks such as pseudoproline dipeptides


cGMP Manufacture

  • Active pharmaceutical ingredients (APIs)
  • Advanced key intermediates

Analytical Support
  • Analytical development and validation
  • Cleaning method development & validation

Quality & Regulatory Support
  • Stability Studies
  • Filing and Maintenance of US-DMFs, EDMFs and others


CordenPharma Switzerland Facility Capacities

Compliance Approvals

Highly cGMP focused and appropriate certificates

  • API manufacturing and Analytical Testing

 
Inspected by Authorities

  • Swissmedic (Quality System Inspections)
    • Bi-annual
    • 2011: 4 minor observations
    • 2013: 4 minor observations
  • US FDA (Pre-approval and Quality System Inspections)
    • 2000: 3 observations on the 483
    • 2004: 0 observations on the 483
    • 2007: 2 observations on the 483
    • 2011: 3 observations on the 483
    • 2014: 0 observations on the 483

Facility Legacy

CordenPharma Switzerland is a cGMP manufacturing facility with expertise in the production of high quality chemical intermediates and active pharmaceutical ingredients including synthetic peptides, lipids and small molecules. Other core competencies include carboydrates, amino acid derivatives and other building blocks such as pseudoproline dipeptides.

Formerly a business unit of Genzyme Corporation, CordenPharma Switzerland brings extensive peptide and amino acid derivative manufacturing capability while adding strength to an existing lipid development and manufacturing business within CordenPharma’s full-service CMO platform.

History

  • 1994 Genzyme Pharmaceuticals acquired Sygena AG, a Swiss facility focused on the production of high quality chemical intermediates and active pharmaceutical ingredients
  • 1999 Sygena officially changed its name to Genzyme Pharmaceuticals
  • 2011 Genzyme Pharmaceuticals acquired by ICIG to become CordenPharma Switzerland